Telomerase activity in patients with transitional cell carcinoma: A preliminary study

Cancer

Volumn 85, Issue 4, 1999, Pages 919-924

  Rahat, Michal A ^a   Lahat, Nitza ^a   Gazawi, Haifa ^a   Resnick, Murray B ^a   Sova, Yanina ^a   Ben Ari, Gad ^a   Cohen, Michael ^a   Stein, Avi ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Bladder; Cup biopsy; Telomerase activity; Transitional cell carcinoma

Indexed keywords

TELOMERASE;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR BIOPSY; URINE; UROTHELIUM;

AGED; BIOPSY; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; NEOPLASM STAGING; TELOMERASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0033557605     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<919::AID-CNCR21>3.0.CO;2-I     Document Type: Article

References (30)

1. Blackburn EH. Structure and function of telomeres. Nature 1991, 350:569-73.
2. Rhyu MS. Telomers, telomerase and immortality. J Natl Cancer Inst 1995;87:884-94.
3. Harley CB, Futcher AB, Greider CW. Telomers shorten during aging of human fibroblasts. Nature 1990;345:458-60.
4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
5. Counter CM, Avilion AA, LeFeurve CE, Stewart NG, Greider CW, Harley CB, et al. Telomers shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-9.
6. Shay JW, Wright WE, Werbin H. Loss of telomeric DNA during aging may predispose cells to cancer, Int J Oncol 1993;3:559-63.
7. Morin GB. Telomere integrity and cancer. J Natl Cancer Inst 1996,88:1095-6.
8. Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta 1991;1072:1-7.
9. Vaziri H, Schächter F, Uchida I, Wei L, Zhu X, Effros R, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993; 52:661-7.
10. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. Telomerase activity in human renal cell carcinima. Oncogene 1996;13:161-6.
11. Sommerfeld H-J, Meeker AK, Paityszek MA, Bova GS, Shay JW. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
12. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990;346:866-8.
13. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, et al. Risk of bladder cancer by source of type of tabacco exposure; a case control study. Int J Cancer 1989; 44:622-8.
14. Friedell GH, Parija GC, Nagy GK, Soto EA. The pathology of human bladder cancer. Cancer 1980;45:1823-31.
15. Lamm D, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. BCG immunotherapy of superficial bladder cancer. J Urol 1980;124:38-40.
16. Stockle M, Wellek S, Meyenburg W, Voges GE, Fischer U, Gertenbach U, et al. Radical cystectomy with or without polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996;48:868-75.
17. Piatyszek MA, Kim NW, Weinrich SL, Hiayama K, Hiyama E, Wright WE, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995;17:1-15.
18. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-9.
19. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori H, Itoh N, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder carcinoma. J Natl Cancer Inst 1997;89:724-30.
20. Müller M, Heine B, Heicappell R, Emrich T, Hummel M, Stein H, et al. Telomerase activity in bladder cancer, bladder washing and in urine. Int J Oncol 1996;9:1169-73.
21. Kyo S, Kunimi K, Uchibayashi T, Namiki M, Inoue M. Telomerase activity in human urothelial tumors. Am J Clin Pathol 1997;107:555-60.
22. Edwards PD, Hurm RA, Jaeschke WH. Conversion of cystitis glandularis to adenocarcinoma. J Urol 1972;108:568-70.
23. Shienfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sangani PC, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990;143:285-8.
24. Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995:46:173-7.
25. Sheinfeld J, Reuter VE, Sarkis AS, Cordon-Cardo C. Blood group antigens in normal and neoplastic urothelium. J Cell Biochem 1992;161:50-5.
26. Murphy WM, Rivera-Ramirez I, Medina CA, Wright NJ, Wajsman Z. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 1997;158:2102-6.
27. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere-White R, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the BTA stat test. Urology 1997;50:349-53.
28. Van Der Poel HG, Van Balken MR, Schamhart DH, Peelen P. Bladder wash cytology, quantitative cytology and qualitative BTA test in patients with superficial bladder cancer. Urology 1998;51:44-50.
29. Johnson B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997;158:2098-101.
30. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al. Use of a new marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7.